News

Study findings show substantial variation in defining and measuring value among existing value assessment frameworks in health care.

Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.

Study findings suggest risk of infusion reactions in patients with CLL receiving obinutuzumab can be reduced using chlorambucil before obinutuzumab administration and by using a slow initial obinutuzumab infusion rate.

Study findings suggest biosimilar intravenous trastuzumab-dkst is cost-efficient over reference intravenous and subcutaneous trastuzumab in metastatic breast cancer.

Study findings suggest that the CARD study population is reflective of real-world clinical practice and that sequential use of androgen-receptor-targeted agents before chemotherapy initiation is common.

Study findings emphasize the value of abiraterone acetate plus ADT given its relative cost-effectiveness to other systemic treatments for metastatic castration-sensitive prostate cancer.

Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.

Findings from a recent study analyzing patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer indicate that PFS gains observed in selected studies of PARP inhibitors may be worth...

Study findings indicate that the introduction of biosimilar bevacizumab-bvzr may provide substantial cost savings from the US payers’ perspective, allowing for the bevacizumab treatment to become accessible to more patients.

Findings from a real-world study suggest that using single-agent ibrutinib for relapsed/refractory CLL is safe and effective in routine clinical practice.